Hence, a survival benefit of renin-angiotensin system blockers treatments has been suggested in patients with solid cancers [15,16,17], through reduction in cancer treatment–related adverse events, such as chemotherapy-induced cardiotoxicity, arterial hypertension and radiation injury [18,19], or possibly through inhibition of tumorigenesis [8]. This evidence concerns the gene REN and cancer.